Video Series

Panelists discuss how key factors such as disease severity, patient preference, and payer requirements influence the choice of initial therapy for alopecia areata (AA), highlighting which drug classes have the highest and lowest success rates.

Panelists discuss how the decision to treat vs observe alopecia areata (AA) depends on factors such as disease severity, patient symptoms, and the use of scoring systems to guide treatment decisions.

Panelists discuss how upcoming ASCO presentations will focus on long-term CAR T-cell therapy outcomes showing potential cure plateaus, minimal residual disease (MRD)–guided treatment escalation/de-escalation strategies, tri-specific antibodies, and the economic value of using MRD negativity to guide maintenance therapy discontinuation decisions.

Sedentary behaviors are associated with increased CVD risk and, when combined with social drivers of health, increase the risk of adverse CVD events like coronary heart disease, stroke, and heart failure.

Social drivers of health are determined primarily by an individual’s economic stability, access to quality education, and health care. These factors also play a key role in the proportion of moderate-to-vigorous-intensity physical activity (MVPA) in an individual’s lifetime, which can also impact their cardiovascular disease (CVD) risk.

Panelists discuss key factors influencing biologic selection for hidradenitis suppurativa, including efficacy, safety, comorbidities, and insurance challenges, highlighting the importance of a holistic, multidisciplinary approach to optimize treatment and navigate practical barriers.

Panelists discuss how academic centers can use telehealth programs like Project ECHO to train community neurologists and ensure consistent, evidence-based MS care across diverse geographic regions.

Panelists discuss how economic models must account for the broader impact of MS progression on earning potential, family planning, caregiver burden, and quality of life rather than focusing solely on direct medical costs.

Panelists discuss the timely initiation of biologic therapy in moderate to severe hidradenitis suppurativa, emphasizing individualized treatment decisions based on disease impact and quality of life, alongside the potential for improved outcomes and cost-effectiveness through early, aggressive management.

An expert discusses the importance of patient education and personalized, flexible treatment planning in managing chronic immune thrombocytopenic purpura (ITP), highlighting proactive strategies like emergency steroids, shared decision-making, and interdisciplinary care to align therapy choices with each patient’s lifestyle, preferences, and comorbidities.

An expert discusses treatment strategies for immune thrombocytopenic purpura (ITP), emphasizing individualized decisions based on platelet count, bleeding symptoms, and comorbidities, with options ranging from observation to urgent therapies like steroids or IVIG, and longer-term approaches tailored to patient health, treatment goals, and lifestyle considerations.

Panelists discuss how managing alopecia areata (AA) involves multiple health care specialties, including dermatology and mental health, and how multidisciplinary care can be optimized, while also addressing strategies to alleviate financial barriers that patients may face in accessing treatment.

Panelists discuss how alopecia areata (AA) is included in the differential diagnosis for hair loss conditions and how a definitive diagnosis is made through clinical evaluation and, when necessary, additional diagnostic tests.

Panelists discuss how recent updates from the phase 3 IsKia trial demonstrate that isatuximab combined with carfilzomib, lenalidomide, and dexamethasone improves minimal residual disease negativity rates by approximately 10% at both the 10–5 and 10–6 levels, particularly benefiting high-risk patients.

Panelists discuss how the PERSEUS trial’s subgroup analysis reinforced that sustained minimal residual disease negativity predicts better long-term outcomes and demonstrated the potential for treatment de-escalation at the 2-year mark, while other trials like Advance showed dramatic increases in MRD negativity rates with quadruplet therapy.

Panelists discuss how patient-reported outcomes are crucial for capturing MS symptoms like fatigue, depression, and cognitive decline that significantly impact working-age patients but require standardization for practical clinical integration.

Panelists discuss the importance of coordinated, personalized treatment strategies for hidradenitis suppurativa, highlighting early use of pharmacologic therapies—including biologics—and ongoing assessment to balance clinical effectiveness, patient quality of life, and financial considerations.

Panelists discuss how clinical trials and real-world studies should focus on patients with PIRA who haven’t experienced relapses for extended periods but continue to accumulate disability.

Panelists discuss the future of NF1-associated plexiform neurofibromas management, highlighting the potential for advances in targeted therapies, gene therapies, and personalized medicine to offer more effective, tailored treatments, while emphasizing early detection, improved imaging, and a greater focus on quality of life through psychosocial support, pain management, and functional rehabilitation.

Panelists discuss optimizing hidradenitis suppurativa management through early intervention, personalized treatment based on disease severity, and multidisciplinary coordination led by dermatologists to improve patient outcomes and reduce disease burden.

An expert discusses treatment strategies for immune thrombocytopenic purpura (ITP), emphasizing individualized decisions based on platelet count, bleeding symptoms, and comorbidities, with options ranging from observation to urgent therapies like steroids or IVIG, and longer-term approaches tailored to patient health, treatment goals, and lifestyle considerations.

An expert discusses the clinical presentation and diagnosis of immune thrombocytopenic purpura (ITP), emphasizing that isolated thrombocytopenia with mucosal bleeding and petechiae is highly suggestive of ITP, while underscoring the importance of ruling out other causes—especially drug-induced thrombocytopenia—through careful evaluation.

Panelists discuss how ongoing or recurrent hair loss in patients with alopecia areata (AA) leads to significant psychological effects, impacting their mental health, and how different forms of AA may be harder for some patients to cope with, with strategies for managing these psychological challenges in clinical practice.

Panelists discuss how alopecia areata (AA) presents with hallmark symptoms such as sudden hair loss, and how the condition fluctuates over time, making it a relapsing or remitting inflammatory disease.

Panelists discuss how emerging evidence from first-line therapy trials continues to demonstrate the superiority of quadruplet over triplet regimens, with the CEPHEUS subgroup analysis confirming that even higher-risk and less-fit patients can benefit from 4-drug combinations while maintaining acceptable safety profiles.

Panelists discuss how quality of life (QOL) and treatment convenience should be balanced with maximal depth of response through personalized therapy approaches, emphasizing the importance of multidisciplinary care teams and the flexibility to adapt treatment regimens based on individual patient preferences and circumstances.

Panelists discuss the significant disparities in hidradenitis suppurativa diagnosis and care, emphasizing the impact of race, gender, geography, and socioeconomic status, and highlighting the need for culturally competent education, expanded access, and community engagement to promote earlier intervention and equitable outcomes.

Panelists discuss how the evaluation process must evolve to accommodate therapies that show benefits in slowing atrophy and motor decline over 1 to 2 years, emphasizing the need for early coverage rather than waiting for extensive long-term data.

Panelists discuss the mechanisms of action of gene therapy for NF1-associated plexiform neurofibromas, focusing on restoring functional neurofibromin to regulate the RAS/MAPK pathway and prevent tumor formation, while highlighting promising early clinical trial results showing reduced tumor volume and improved symptoms, alongside the need for further studies to assess long-term safety and efficacy.

Panelists discuss the vital role of multidisciplinary collaboration, provider education, and technology integration in improving early diagnosis and comprehensive management of hidradenitis suppurativa, highlighting how coordinated efforts across specialties—including pharmacists—can reduce delays, enhance equity, and optimize patient outcomes.